Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n°: NCT05130853).
metacognition
narrative enhancement
real-life functioning
schizophrenia
social cognition training
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
12
2021
accepted:
17
02
2022
entrez:
21
4
2022
pubmed:
22
4
2022
medline:
22
4
2022
Statut:
epublish
Résumé
Subjects affected by schizophrenia present significant deficits in various aspects of social cognition, such as emotion processing, social perception and theory of mind (ToM). These deficits have a greater impact than symptoms on occupational and social functioning. Therefore, social cognition represents an important therapeutic target in people with schizophrenia. Recent meta-analyses showed that social cognition training (SCT) is effective in improving social cognition in subjects with schizophrenia; however, real-life functioning is not always ameliorated. Integration of SCT with an intervention targeting metacognitive abilities might improve the integration of social cognitive skills to daily life functioning. Our research group has implemented a new individualized rehabilitation program: the Social Cognition Individualized Activities Lab, SoCIAL, which integrates SCT with a module for narrative enhancement, an intervention targeting metacognitive abilities. The present multi-center randomized controlled study will compare the efficacy of SoCIAL and treatment as usual (TAU) in subjects diagnosed with a schizophrenia-spectrum disorder. The primary outcome will be the improvement of social cognition and real-life functioning; while the secondary outcome will be the improvement of symptoms, functional capacity and neurocognition. The results of this study will add empirical evidence to the benefits and feasibility of SCT and narrative enhancement in people with schizophrenia-spectrum disorders.
Identifiants
pubmed: 35444577
doi: 10.3389/fpsyt.2022.833550
pmc: PMC9015661
doi:
Types de publication
Journal Article
Langues
eng
Pagination
833550Informations de copyright
Copyright © 2022 Palumbo, Caporusso, Piegari, Mencacci, Torriero, Giuliani, Fabrazzo, Pinto and Galderisi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Schizophr Bull. 2015 Jul;41(4):781-5
pubmed: 25750248
Am J Psychiatry. 2008 Feb;165(2):214-20
pubmed: 18172018
World Psychiatry. 2019 Jun;18(2):165-167
pubmed: 31059625
Schizophr Bull. 2020 Mar 12;:
pubmed: 32162658
Psychiatr Serv. 2007 Apr;58(4):449-51
pubmed: 17412842
World Psychiatry. 2019 Oct;18(3):274-275
pubmed: 31496075
Schizophr Res. 2018 Nov;201:180-186
pubmed: 29910120
World Psychiatry. 2020 Oct;19(3):309-310
pubmed: 32931097
World Psychiatry. 2019 Jun;18(2):117-118
pubmed: 31059631
World Psychiatry. 2019 Jun;18(2):162-163
pubmed: 31059615
JAMA Psychiatry. 2018 Apr 1;75(4):396-404
pubmed: 29450447
Schizophr Bull. 2021 Jan 23;47(1):108-117
pubmed: 32614046
Eur Arch Psychiatry Clin Neurosci. 2010 Jun;260(4):305-15
pubmed: 19826855
Schizophr Res. 1997 May 3;25(1):21-31
pubmed: 9176924
Schizophr Bull. 2007 Nov;33(6):1364-72
pubmed: 17341468
Clin Orthop Surg. 2014 Mar;6(1):103-9
pubmed: 24605197
J Abnorm Psychol. 1993 May;102(2):312-8
pubmed: 8315144
Dialogues Clin Neurosci. 2014 Jun;16(2):185-95
pubmed: 25152657
Schizophr Bull. 2011 Sep;37 Suppl 2:S63-70
pubmed: 21860049
Schizophr Res. 2007 Jul;93(1-3):278-87
pubmed: 17407806
Psychol Med. 2018 Jun;48(8):1359-1366
pubmed: 29017620
Schizophr Res. 2015 Feb;161(2-3):386-91
pubmed: 25499045
Schizophr Bull. 2011 Sep;37 Suppl 2:S41-54
pubmed: 21860046
J Head Trauma Rehabil. 2003 May-Jun;18(3):219-38
pubmed: 12802165
Schizophr Res. 2016 Aug;175(1-3):154-160
pubmed: 27209527
Lancet Psychiatry. 2018 Aug;5(8):664-677
pubmed: 29602739
World Psychiatry. 2020 Oct;19(3):401-402
pubmed: 32931108
Neuropsychology. 2009 May;23(3):315-36
pubmed: 19413446
Health Qual Life Outcomes. 2003 Oct 23;1:60
pubmed: 14613562
Am J Psychiatry. 2009 Jun;166(6):675-82
pubmed: 19369319
J Clin Psychol. 2014 Apr;70(4):303-12
pubmed: 24114797
Schizophr Bull. 2008 Jul;34(4):670-2
pubmed: 18495642
Conscious Cogn. 2010 Mar;19(1):328-40
pubmed: 19955004
Dialogues Clin Neurosci. 2019 Sep;21(3):309-317
pubmed: 31749655
World Psychiatry. 2019 Feb;18(1):67-76
pubmed: 30600629
Schizophr Bull. 2001;27(2):235-45
pubmed: 11354591
Am J Psychiatry. 2008 Feb;165(2):203-13
pubmed: 18172019
Schizophr Res. 2014 Sep;158(1-3):156-62
pubmed: 25086658
Eur Psychiatry. 2021 Feb 18;64(1):e23
pubmed: 33597064
Soc Psychiatry Psychiatr Epidemiol. 2017 Nov;52(11):1415-1423
pubmed: 28424854
World Psychiatry. 2019 Jun;18(2):171-172
pubmed: 31059612
Schizophr Bull. 2003;29(3):427-44
pubmed: 14609238
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Nord J Psychiatry. 2010;64(1):63-7
pubmed: 20092378
Acta Psychiatr Scand. 2005 Jul;112(1):64-71
pubmed: 15952947
World Psychiatry. 2019 Jun;18(2):168-170
pubmed: 31059610
World Psychiatry. 2020 Jun;19(2):254-255
pubmed: 32394552
CNS Spectr. 2019 Feb;24(1):88-93
pubmed: 30683165
Schizophr Bull. 2013 May;39(3):507-17
pubmed: 23125396
World Psychiatry. 2020 Feb;19(1):117-119
pubmed: 31922675
World Psychiatry. 2020 Feb;19(1):81-91
pubmed: 31922687
Compr Psychiatry. 2016 Aug;69:53-61
pubmed: 27423345
Psychother Psychosom. 2009;78(5):275-84
pubmed: 19602916
Schizophr Res. 2013 Oct;150(1):69-75
pubmed: 23962828
Neuropsychiatr Dis Treat. 2017 Jul 20;13:1947-1956
pubmed: 28790830
Psychiatry Res. 2008 Jan 15;157(1-3):31-8
pubmed: 18023881
World Psychiatry. 2019 Jun;18(2):146-161
pubmed: 31059632
Community Ment Health J. 2020 Feb;56(2):211-221
pubmed: 31664623
World Psychiatry. 2019 Jun;18(2):235-236
pubmed: 31059624
World Psychiatry. 2014 Oct;13(3):275-87
pubmed: 25273301
World Psychiatry. 2019 Feb;18(1):53-66
pubmed: 30600626
World Psychiatry. 2019 Feb;18(1):3-19
pubmed: 30600616
World Psychiatry. 2019 Jun;18(2):163-164
pubmed: 31059607
Am J Psychiatry. 2002 Jun;159(6):983-90
pubmed: 12042187
Soc Psychiatry Psychiatr Epidemiol. 2019 Nov;54(11):1363-1378
pubmed: 30937510
Clin Psychopharmacol Neurosci. 2018 Feb 28;16(1):7-17
pubmed: 29397662
World Psychiatry. 2020 Oct;19(3):381-388
pubmed: 32931122
World Psychiatry. 2019 Jun;18(2):170
pubmed: 31059619
Psychiatry Res. 2009 Apr 30;166(2-3):141-7
pubmed: 19272654
World Psychiatry. 2020 Oct;19(3):390-391
pubmed: 32931093
World Psychiatry. 2020 Jun;19(2):151-172
pubmed: 32394571
BMC Psychiatry. 2021 Jul 2;21(1):329
pubmed: 34215225
Fortschr Neurol Psychiatr. 2008 May;76 Suppl 1:S57-62
pubmed: 18461546
World Psychiatry. 2020 Jun;19(2):177-178
pubmed: 32394575
JAMA Psychiatry. 2021 May 1;78(5):550-559
pubmed: 33566071
Disabil Rehabil. 2006 Dec 30;28(24):1529-42
pubmed: 17178616
J Clin Psychol. 1992 Mar;48(2):239-45
pubmed: 1573027
Psychiatry Res. 1994 Jul;53(1):31-40
pubmed: 7991730
Neuropsychopharmacol Hung. 2015 Sep;17(3):129-40
pubmed: 26485743
Psychiatry (Edgmont). 2010 Feb;7(2):41-4
pubmed: 20376275
Schizophr Bull. 2016 Jan;42(1):56-66
pubmed: 26209548
World Psychiatry. 2019 Jun;18(2):164-165
pubmed: 31059634
Expert Rev Neurother. 2010 Jan;10(1):43-57
pubmed: 20021320
Schizophr Bull. 2012 Sep;38(5):1092-104
pubmed: 21525166
Am J Psychiatry. 2007 Dec;164(12):1791-802
pubmed: 18056233
Schizophr Res. 2008 Oct;105(1-3):68-77
pubmed: 18585899
PLoS One. 2017 Aug 24;12(8):e0183614
pubmed: 28837678
Schizophr Res. 2004 Dec 1;71(2-3):285-95
pubmed: 15474899
World Psychiatry. 2019 Jun;18(2):167-168
pubmed: 31059617
Schizophr Res Cogn. 2014 Mar;1(1):e1-e9
pubmed: 25254156